Dr. Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Roswell Park Comprehensive Cancer Center
Elm and Carlton Street
Buffalo, NY 14263Phone+1 716-845-3239Fax+1 716-845-8261
Summary
- Dr. Michael Wong is an oncology specialist based in Buffalo, NY, with a focus on melanoma, rare skin cancers and novel therapeutics. He completed his medical education at the University of Toronto Faculty of Medicine in 1989. Currently, he serves as the Physician in Chief at Roswell Park Comprehensive Cancer Center. Dr Wong was previously professor at the University of Texas M.D. Anderson Cancer Center and Medical Executive for Integration and Special Programs for the MD Anderson Network. Dr. Wong was also the Adams Endowed Chair in Cancer Research, and Head of Solid Tumor Division at the University of Southern California. He is an expert in Drug Development including Small Molecules, Cytokines, Checkpoint Inhibitors and Oncolytic Vaccines. His clinical practice includes Melanoma, Merkel Cell Carcinoma, and other rare skin cancers.
Education & Training
- University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2016 - 2026
- NY State Medical License 2003 - 2025
- CA State Medical License 2010 - 2024
- OK State Medical License 2020 - 2021
- PA State Medical License 1998 - 2004
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Publications & Presentations
PubMed
- 1 citationsImmune Checkpoint Inhibitor Therapy for Periocular Merkel Cell Carcinoma.Joshua Hohlbein, Janet Fan, Hila Goldberg, Tracy Lu, Anastasios Maniakas
Ophthalmology. 2025-01-01 - 1 citationsSurvival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.Chantal Saberian, Denái R Milton, Julie Simon, Rodabe N Amaria, Adi Diab
Neuro-Oncology Practice. 2024-08-01 - Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett Jr, Alexandra P Foster, Ida John
Nature Medicine. 2024-06-01
Press Mentions
- "Taking the Journey - Ella's Story" - A UC Davis Health Patient TestimonialOctober 17th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: